Lower riskDrug recall · FDA · Published August 27, 2019
American Health Packaging Lamivudine Tablets Recall: Incorrect Labeling Risk
American Health Packaging recalls Lamivudine 150mg tablets with incorrect labeling that may cause dosage confusion. Affected lots expire June 2021. Consumers should check NDC 60687-362-21.
Labeling: Incorrect or Missing Package Insert; an error in the Dosage Forms and Strengths section of the insert that incorrectly lists the tablet description coding for the tablets.
Take action
Contact the company
📍Recalling firmAmerican Health Packaging2550 John Glenn Ave Ste A · Columbus, OH 43217-1188
“American Health Packaging Lamivudine Tablets Recall: Incorrect Labeling Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/38069-american-health-packaging-lamivudine-tablets-recall-incorrect-labeling-risk. Based on FDA recall #D-1847-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1847-2019%22&limit=1).
The FDA announced on 2019-08-27 that American Health Packaging voluntarily recalled Lamivudine Tablets, USP, 150 mg due to labeling errors in the package insert, according to FDA records. The recall affects lots expiring 6/30/2021 distributed nationwide.
The hazard involves incorrect or missing package inserts, specifically an error in the Dosage Forms and Strengths section that incorrectly lists the tablet description coding for the tablets.
Context
GovInfoNow's records show American Health Packaging has 41 other recalls on record since 2012-07-23. Other recent recalls of similar products include American Health Packaging Buprenorphine Tablets Recall (2026-08-19), American Health Packaging Nitrofurantoin Capsules Recall (2022-05-03), and American Health Packaging Recalls Cyanocobalamin Injection Due to Subpotent Drug (2022-04-12). Other recent recalls of similar products include American Regent Levocarnitine Injection Recall (2026-04-16), Sun Pharmaceutical Perampanel 6mg Tablets Recall (2026-06-17), and Meclizine 12.5mg Tablets Recall (2026-03-16).
How to tell if you have this one
Check for the NDC code 60687-362-21 on the product packaging. The affected lots are 186509 and 186982, expiring June 30, 2021.
Brand
American Health Packaging
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Label
Look for the NDC code 60687-362-21 on the product packaging to confirm if it's affected.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 12 months after the firm started it.
1Firm started the recall
2FDA classified it Class III
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-1847-2019 (August 27, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1847-2019 to see it in context.
Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.